The earnings call reflected strong growth in flagship products like PYLARIFY and DEFINITY, boosted by strategic initiatives and positive regulatory developments. However, these were slightly tempered by sequential revenue declines and challenges with clinical trials for PNT2002. Overall, the financial performance and strategic advancements support a positive outlook.

Company Guidance

During the Lantheus Q3 2024 earnings call, the executives provided guidance that highlighted the company's strong performance and future expectations. PYLARIFY, their leading PSMA PET imaging agent, achieved approximately $260 million in net sales for the quarter, reflecting a 20% year-over-year increase, and is on track to reach blockbuster status with over $1 billion in sales in 2024. DEFINITY, their ultrasound enhancing agent, reported third-quarter net sales of $77 million, marking a 14% year-over-year growth. Lantheus also announced the company's 2024 revenue guidance, which has been narrowed to a range of $1.51 billion to $1.52 billion, with an expected mid-20% growth for PYLARIFY over 2023. Additionally, adjusted EPS for the full year is projected to be between $6.65 and $6.70. The company is also optimistic about the CMS decision to provide separate payment for specialized diagnostic radiopharmaceuticals, which is anticipated to benefit patient access and innovation in the field.

Record-Breaking PYLARIFY Performance

PYLARIFY sustained its market leadership as the #1 PSMA PET imaging agent, with net sales reaching approximately $260 million for the quarter, marking a 20% year-over-year growth. It remains on track to reach blockbuster status in 2024.

Strong DEFINITY Growth

DEFINITY delivered third-quarter net sales of $77 million, increasing 14% year-over-year, driven by competitor supply challenges and high single-digit market growth.

Strategic CMS Policy Update

CMS announced its decision to pay separately for specialized diagnostic radiopharmaceuticals starting January 1, 2025, ensuring improved patient access and support for long-term innovation.

Solid Financial Performance

Consolidated net revenue for the third quarter was $378.7 million, an increase of 18.4%. Adjusted net income rose 20.4% to $124.1 million.

Emerging Alzheimer's Diagnostic Portfolio

Lantheus is advancing MK-6240 and NAV-4694, with potential U.S. market estimates for Alzheimer's radio diagnostics reaching $1.5 billion by the end of the decade.

---

Lantheus Holdings Inc (DE:0L8) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

DE:0L8 Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Aug 01, 2018	2018 (Q2)	- / 0.25	0.41	-38.10% (-0.16)	―	―
Oct 30, 2018	2018 (Q3)	- / 0.23	0.234	0.00% (0.00)	―	―
Feb 19, 2019	2018 (Q4)	- / 0.28	0.117	141.67% (+0.17)	―	―
Apr 30, 2019	2019 (Q1)	- / 0.27	0.215	27.27% (+0.06)	―	―
Jul 25, 2019	2019 (Q2)	- / 0.26	0.254	3.85% (<+0.01)	―	―
Oct 31, 2019	2019 (Q3)	- / 0.27	0.234	16.67% (+0.04)	―	―
Feb 25, 2020	2019 (Q4)	- / 0.33	0.283	17.24% (+0.05)	―	―
Apr 30, 2020	2020 (Q1)	- / 0.35	0.273	28.57% (+0.08)	―	―
Jul 30, 2020	2020 (Q2)	- / 0.10	0.263	-62.96% (-0.17)	―	―
Nov 05, 2020	2020 (Q3)	- / 0.04	0.273	-85.71% (-0.23)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

---

DE:0L8 Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Nov 06, 2024	€105.75	€106.75	+0.95%
Jul 31, 2024	€102.35	€102.25	-0.10%
May 02, 2024	€62.36	€62.40	+0.06%
Feb 22, 2024	€52.26	€60.08	+14.96%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

---